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Background: Dengue is the most prevalent and fast spreading arboviral infection affecting people. No specific
drug is available to treat dengue. Thrombocytopenia with potential of serious hemorrhages is one of the hall mark
features of dengue. Immune thrombocytopenic purpura is an autoimmune disease causing thrombocytopenia. If a
patient with that gets dengue, we expect severe thrombocytopenia with bleeding manifestations. Only a handful of
such cases were reported before, and they were managed in different ways.
Case presentation: A 30-year-old Sinhalese man recently diagnosed of immune thrombocytopenic purpura and
on prednisolone was presented on the fourth day of fever, head ache, arthralgia, myalgia, and nausea. We started
standard symptomatic dengue management and continued prednisolone. Dengue IgM and IgG antibody tests
became positive. He was monitored by physical signs and serial full blood counts as the mainstay of monitoring.
The patient never developed clinical bleeding manifestations and recovered.
Conclusions: Considering the huge population at risk of dengue, generating more evidence on the topic and
formulation of effective, simple guidelines to manage dengue in children and adults with immune
thrombocytopenic purpura is going to be beneficial for many patients in the future.
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Dengue is an emerging viral hemorrhagic fever with rare
severe forms, transmitted by female Aedes mosquitoes.
Management of clinical dengue is symptomatic because no
specific antiviral drug is available [1–3]. Thrombocytopenia
due to activation of complex immune mechanisms and
direct dengue virus action on bone marrow is one of the
hallmark features of dengue [2–5]. In severe dengue,
disseminated intravascular coagulation can contribute to
thrombocytopenia [5]. Platelet count is considered to
correlate with the severity of dengue [2]. Serial platelet
counts are a key laboratory investigation parameter in
managing dengue patients. In some severe dengue cases, a
combination of thrombocytopenia with other factors lead* Correspondence: drehelepola@gmail.com
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Immune thrombocytopenic purpura (ITP) also known
as idiopathic thrombocytopenic purpura or immune
thrombocytopenia is a hematological disorder resulting
thrombocytopenia caused due to a primary or secondary
autoimmune process [6]. It also can cause serious
bleeding manifestations. Therefore, if a patient is
diagnosed with ITP get infected with dengue, we,
doctors, are more concerned and expect him/her to
develop severe thrombocytopenia and bleeding manifes-
tations. The current strongest estimate of the incidence
of ITP is 3.3 per 100,000 adults per year [7]. Dengue
incidence has dramatically risen around the world in
recent decades [8]. Therefore, many patients with ITP
are likely to get dengue infection at present and in the
future, and it is important to be aware of thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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there are no guidelines regarding of management of such
patients. We were surprised to read in one paper [4] that
only four such cases were reported up to 2012 world-
wide and none from Asia Pacific, the region with highest
burden of dengue. We found one case report of a child
from India [9]. Clinical course of ITP of children differs
from adults [6]. Here, we report a case of an adult with
recently diagnosed ITP getting dengue and recovered
without developing any clinical bleeding manifestations.
All four serotypes of dengue virus co-circulate in Sri
Lanka, but the predominant serotype since 2009 is
DENV1 [10]. With the above background, we think this
case report will be interesting to many readers.
Case presentation
A 30-year-old Sinhalese man was presented to us with
history of high fever, head ache, generalized myalgia, arth-
ralgia, loss of appetite, and nausea on the fourth day of the
illness. He gave a history of digging a well a week before
onset of fever and working at a rice paddy (exposure to
leptospirosis). Leptospirosis was endemic, and a dengue
epidemic was going on in his locality at that time. Six
weeks ago, he developed a purpuric skin rash affecting all
limbs with pruritus. After investigations including a bone
marrow biopsy, a consultant hematologist has diagnosed
ITP and started oral prednisolone and omeprazole. At the
onset of his present illness, he has been on those drugs.
He was also on topical clobetasol cream from a dermatol-
ogy clinic for a patch of hypertrophic lichen planus at his
left wrist. Apart from those, he was healthy.
On examination, he was not icteric or pale and had no
skin rashes other than lichen planus rash. His pulse rate
was 88/min, and blood pressure was 100/70 mmHg
without a postural drop. Auscultation of lungs and
abdominal examination was unremarkable. His oxygen
saturation was 97 %.
Two most probable differential diagnoses were dengue
and leptospirosis. Standard dengue fever management
[1, 3] started, and in addition, intravenous crystalline
penicillin was prescribed to cover leptospirosis. His skin
sensitivity test for crystalline penicillin became positive.
Hence, it was substituted with oral doxycycline, and
prednisolone and omeprazole were continued.
Since his myalgia and arthralgia did not respond to
oral paracetamol (acetaminophen) given pro re nata, a
regular dose of oral tramadol was added. Oral calcium
lactate was given from day 5 of the illness. On the
seventh day of the illness, both dengue IgM and IgG
were positive. Doxycycline was discontinued thereafter.
Table 1 summarizes his laboratory investigation results.
His fever subsided after the sixth day of illness and
never recurred. He developed marked flushing of the skin
and conjunctival injection after the fifth day of illness thatimproved by the tenth day but never had any purpura or
other bleeding manifestations; daily tourniquet tests were
also negative during his hospital stay. He was sent home
after 8 days and reassessed once and advised to continue
to attend his hematology clinic. One week after discharge,
his white cell count was 7.68 × 109/l (neutrophils 72.7 %
and lymphocytes 23.4 %), hemoglobin level was 14.9 g/dl
with a hematocrit of 43.9 %, and the platelet count has
risen to 97 × 109/l. We did fasting blood sugar level test as
well as he has been on steroids and it was also normal
(4.1 mmol/l).
Discussion
We discussed the relevant issues under four subheadings.
Diagnosis of dengue in this patient
A dengue epidemic was going on in his locality when he
presented. His symptoms and signs were compatible
with dengue. His laboratory reports also favor diagnosis
of dengue (leucocytopenia, invertion of neutrophils to
lymphocyte ratio on the seventh day of illness and again
reversing, serial changes of his platelet count, serial
changes of his hematocrit). Finally, positive dengue IgM
and IgG tests confirmed the diagnosis. Infection with
other flavoviruses can give false positives in IgM and
IgG tests. Japanese encephalitis (JE) is the other flavo-
virus disease in Sri Lanka, and it is rare. JE is very rare
in the central hill country where the patient lives and he
has never traveled abroad and never got vaccinated
against JE. Considering all, we can conclude this as a
dengue case.
Comparison of this case with results of some past studies
on thrombocytopenia and bleeding in dengue. Why he did
not bleed?
Past studies from Sri Lanka and other countries show that
in children with dengue, there is little correlation between
platelet count and bleeding manifestations [4, 11, 12]. One
study involving adult dengue patients demonstrated
platelet counts <5 × 109/l and hematocrit >50 % were
significantly associated with bleeding manifestations. An-
other study suggested that bleeding occurred more often
when platelet counts <20 × 109/l that necessitate platelet
transfusion [13]. However, one study done on adult den-
gue patients demonstrated no correlation between clinical
bleeding and platelet count, and one third of their non-
bleeding patients had counts <20 × 109/l [14]. Before start-
ing prednisolone, our patient had a purpuric rash
although his platelet counts were higher. His platelet
count did not drop below those risky levels, and the
lowest was 20 × 109/l in the morning of the eighth day of
illness but quickly improved without any bleeding
manifestations. The above evidences explain why he did
not bleed.









Day 5 Day 6 Day 7 Day 8
Day of illness Day4 Day5 Day6 Day 7 Day 8 Day 9 Day 10 Day 11
White cell count 
(×109/l)
4.0−10.0×109/l 4.98 1.53 1.62 3.13
Neutrophils ( ) 50−70% 42.1 67 54.2 66.2
Lymphocytes ( ) 20−40% 36.0 25.5 37.5 24.3
Hemoglobin (g/dl) 11−16% 13.3 14.0 14.3 15.5 14.5
Hematocrit ( ) 37−54% 39.3 41.2 41.5 48.2 42.1
Platelets count 
(×109/l)
150−450×109/l 77 35 37 41 35
Dengue IgM and 
IgG
antibodies






















Urine full report No protein Protein-trace
No red cells
38 43 30 21 25 28 20 21 51 55
Platelet counts are captured in bold. Full (complete) blood count (FBC) done 6 weeks before is shown to get an idea of baseline (before starting prednisolone). No
FBC immediately before onset of symptoms is available
aSerum alanine transaminase (ALT) is also known as serum glutamic pyruvic transaminase (SGPT)
bSerum aspartate transaminase (AST) is also known as serum glutamic oxaloacetic transaminase (SGOT)
Ehelepola et al. Tropical Medicine and Health  (2016) 44:36 Page 3 of 5What could have prevented severe thrombocytopenia, role
of prednisolone
We wondered what prevented his platelet count drop-
ping too low. The most likely possibility is he got a less
severe form of dengue hemorrhagic fever (DHF). We
speculate whether prednisolone he was on also might
have helped him. Some of us and many other doctors
known to us have used prednisolone, hydrocortisone,
and methyl prednisolone to manage severe dengue, and
in fact, some of us were treated with steroids as dengue
patients in the past. There was a debate within the Sri
Lankan medical fraternity of the use of steroids in
dengue, and present dominant view is steroids are not
beneficial. Complying with the latest national guidelines
[3], we also have stopped using them except for especial
cases like in this patient. Thrombocytopenia and
capillary leakage (the corner stone of severe dengue),
both are mainly resulting due to immune mechanisms.
Temporary reversible disruption of the surface glycoca-
lyx, a lining in the vascular endothelium that regulates
microvascular filtration, is attributed to transient
capillary leakage in dengue [15]. Immune mechanisms
play a role in increased peripheral destruction ofplatelets and impairment of platelet functions in dengue
[5]. Steroids blunt both innate and acquired immunity
mechanisms responsible for these changes. There are
evidences indicating that steroids modulate the function
of the endothelial glycocalyx and may prevent damage to
this layer [15]. We generally expect steroids to com-
promise immunity and favor viral replication. Viral load
was correlated to severity of dengue in the past studies
[2]. However, a laboratory study has shown that cortico-
steroids do not increase dengue viral replication in cell
culture [15]. A randomized, placebo-controlled, blinded
trial also showed that both low-dose and high-dose
prednisolone therapy during viremic phase of dengue is
not associated with prolongation of viremia or other
adverse effects [15]. Nevertheless, this study did not
show any benefits of prednisolone in preventing severe
thrombocytopenia, shock or other complication of
dengue as well [15]. Another placebo-controlled study
employing sealed envelope randomization done in Sri
Lanka showed low-dose intravenous dexamethasone was
not effective in achieving a higher rise of platelet count
in dengue infection [16]. According to the Cochrane re-
view, there is insufficient evidence to evaluate the effects
Ehelepola et al. Tropical Medicine and Health  (2016) 44:36 Page 4 of 5of corticosteroids in dengue at present [17]. However,
the only other similar reported case who was also on
steroids at the onset of fever and continued to receive
steroids like our patient recovered after only having
petechial hemorrhages [9]. His platelet count also did
not fall <20 × 109/l, and those authors mention that they
contemplated to increase steroid dose in the case of
bleeding or platelet counts dropping below that level [9].
Hence, steroids may be beneficial, at least unlikely to be
harmful in treating dengue in diagnosed ITP patients
when we consider above evidences. However, available
evidences on the subject are inadequate to come to a
reasonable conclusion.
Comparison of our management with that of other
reported cases
An Indian boy who was also on steroids at the onset of
dengue and continued to receive steroids like our patient
recovered after only having petechial hemorrhages [9].
Other reported cases are from Americas. They were
managed in different ways such as high doses of cortico-
steroids [18, 19], intravenous immunoglobulins (IVIG) [4],
IVIG with steroids and platelet transfusion [19], and
platelet and other blood product transfusion [20]. One
11-year-old Brazilian girl died [20]. Others recovered, and
unlike our patient, most of them have previously undergone
splenectomy. Some past studies indicate patients under-
gone splenectomy may be less susceptible to development
of severe forms of dengue [4]. However, all of them had
bleeding manifestations unlike our patient. Innate immun-
ity and both humoral and cell-mediated immune processes
are known to contribute to the pathogenesis of dengue
hemorrhagic fever [2]. Unlike IVIG, steroids blunt all those
immune processes. That might be a reason for no bleeding
of our patient and minimal bleeding manifestations of the
Indian boy. Nevertheless, some other reported patients
received steroids also had bleeding, but steroids were
started late in them [19].
It is interesting to note one Cuban patient was treated
symptomatically, and there was a steep transient rise of
platelet count much above her baseline level on the 15th
day after onset of fever [21]. Our patient’s platelet count
did not show such a rise. Persistence of thrombocytopenia
(or onset of ITP) after dengue infections were also
reported [22]. In contrast, our patient’s platelet count
improved in days.
Conclusions
Further studies involving larger numbers of patients
would be helpful to determine whether steroids are bene-
ficial and to formulate the best ways to manage dengue in
adults and children with ITP. There is an acute need for
such studies because 3.9 billion people, in 128 countries,
are at risk of infection with dengue viruses at present [8].Abbreviations
ALT: Alanine transaminase; AST: Aspartate transaminase; DHF: Dengue
hemorrhagic fever; ITP: Immune thrombocytopenic purpura; IVIG: Intravenous
immunoglobulins; JE: Japanese encephalitis
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